Medical implant

Information

  • Patent Grant
  • 11426293
  • Patent Number
    11,426,293
  • Date Filed
    Thursday, May 23, 2019
    4 years ago
  • Date Issued
    Tuesday, August 30, 2022
    a year ago
Abstract
A medical having a proximal and a distal end, that is preformed to assume a superimposed structure at an implantation site but can be made to take on a volume-reduced form making it possible to introduce it by means of a micro-catheter and a guide wire arranged at the proximal end, with the implant in its superimposed structure assuming the form of a longitudinally open tube and having a mesh structure of interconnected strings or filaments. The implant has a tapering structure at its proximal end where the strings or filaments converge at a connection point.
Description
FIELD OF THE INVENTION

The present invention relates to a medical implant that is preformed in order to assume, at the site of implantation, a superimposed structure and while being implanted is presented in a volume-reduced form. Furthermore, the present invention relates to the application of such an implant as a neuro-stent, its combination with a guide wire as well as a system for the application of such implants when treating aneurysms or other vascular malformations.


BACKGROUND OF THE INVENTION

It is known to treat vasoconstriction (stenoses) with stents (vascular endoprostheses, vessel props) that are inserted into the stenotic area to keep the vessel lumen open. It is further known to use such stents for closing off vessel wall ballooning (aneurysms) or fistulae.


For the foregoing purposes, balloon-dilatable stents are traditionally used. For placement, these stents are crimped over a non-expanded balloon in a non-dilated state, moved to the treatment location by means of a catheter system and then, by expanding the balloon, dilated and thus anchored within the vessel. As there is no need for sophisticated supporting and guiding sheaths when placing balloon-dilatable stents in position, these stents can also be inserted into very fine vessels. It is, however, problematic that on account of their plastic deformability these stents can easily be compressed when external pressure is exerted on them. Another disadvantage is encountered when anchoring such a stent, by applying high pressure, the stent has to be expanded initially beyond the circumferential size it will finally have. Such an expansion beyond the required circumferential size may involve the risk of a vessel injury that may entail the formation of a thrombus.


Further, these traditional balloon-dilatable stents, due to their structure, cannot simply be introduced through an already laid micro-catheter and advanced to the implantation site but have to be arranged in the distal area of a specially designed micro-catheter in order to be moved to the implantation location by means of a so-called pusher. This process calls for a rather sophisticated catheter technology that is difficult to handle. Additionally, a stent, once placed in position, can only be relocated or retrieved with great difficulty, if at all. After a wrongly placed stent has been dilated it can neither be relocated nor removed as a rule.


It is further known to apply self-expanding stents that are made of shape memory materials. These stents possess a braid-like structure and are initially introduced and moved in a collapsed state through a catheter to the destination site where they expand either due to temperature changes (thermo-memory effect) or because the mechanical force exerted by the catheter (super-elasticity) is no longer effective. Such stents, as well, require mechanisms for their introduction that are relatively expensive and space-consuming. The known super-elastic expandable stent requires the use of a supporting and guiding sheath that results in a relatively large catheter size and, what is more, also makes it difficult to introduce such stents through an already laid catheter.


For the introduction into small-lumen intra-cranial vessels, it is furthermore known to use stents made of shape-memory materials that initially are present in the form of an elongated filament. Not until the stent exits the catheter will it assume its tubular structure due to the change in temperature or because of the compression force no longer being exerted by the catheter.


It is known to treat aneurysms and similar diseases by using a stent consisting of two stretched out filaments that due to the mechanical constraint of a strand, are kept, by tension, in the stretched out form until when pushed out of the catheter, said constraint is removed and the strands assume the actual form of a stent. This structure enables the use of stents having shape-memory properties in vessels of very small lumen such as the intra-cranial and cerebral vessel branches.


SUMMARY OF THE INVENTION

The present invention is directed to implants that can be introduced through traditional micro-catheters into small-lumen intra-cranial vessels, that are well placeable and relocatable, that can be moved back into the micro-catheter in case of need, and that are suited to bridge vessel ballooning and fistulae in such a manner that these can be filled with occlusion agents. Furthermore, it is desirable to provide implants capable of adapting to the vessel caliber relatively freely, i.e., not tailored to a specific vessel caliber.


According to the present invention, a medical implant that has the form of a longitudinally open tube with interconnected strings or filaments forming a mesh structure culminating, on one side, in a tapering structure at a connection point is provided.


An implant according to the present invention consists of a flat object that, as a result of its impressed and superimposed structure, assumes the form of a slotted tube or hose with the free edges preferably overlapping. In its volume-reduced form it continues to be present in a curled-up condition, i.e., the diameter of the implant, in a volume-reduced state, is significantly reduced in comparison to that of the superimposed structure. After the implant has been released, it assumes the structure impressed on it and expands to such an extent that the vessel surrounding the implant allows. Such an expansion in the form of an expanding spiral spring shape leads to the implant automatically adapting to the vessel caliber or lumen in such a manner that it can be applied in vessels having different calibers. In the case of narrow vessels, this results in a relatively wide overlap of the two free edges, with wider vessels this overlap is smaller or even a free gap forms which, in the event of vessel branches, is a desirable trait.


In one aspect of the present invention, the implant is a flat or two-dimensional structure that is rolled up to form a longitudinally open object capable of establishing dose contact with the wall of the vessel into which it is introduced.


The strings or filaments taper on one side and culminate in a connection point that permits the implant to be connected to a guide wire to be easily retracted into a catheter in an event of an incorrect placement or inadequate adaptation to the implantation site so that it may be replaced by another implant or reimplanted after the catheter has been repositioned. As a result of its tapering structure, the implant entering the micro-catheter curls up more closely and again assumes its volume-reduced form with the pull force applied to the guide wire and the forces exerted via the catheter rim interacting.


In the catheter itself, the implant is present in its volume-reduced form, resembling rolled up wire netting, Through the action of the guide wire and when thrust forces are applied, an axial compression will be caused, and when released, the superimposed structure assumes a minor longitudinal contraction. Advantageously, the stent according to the present invention exhibits an insignificant longitudinal contraction when released in comparison to dilatable stents.


A connection point of the medical implant situated at the end of the tapered structure serves, at the same time, as a fastening point for the guide wire, either directly or via a connecting elements In the event of a cut or expanded metal foil, this connection point represents the point where the strings of the implant converge. In the case of a mesh-like structure consisting of individual filaments, at least two filaments converge at this connection point and are connected with each other by welding or crimping.


The connection point serves also as a connecting element or part thereof that remains attached to the implant after the guide wire has been detached from the implant. In one embodiment, this connection point is arranged within a platinum spiral or attached to it via a platinum spiral to a connecting element. The spiral may also serve as an X-ray reflecting marker for positioning purposes. In one embodiment the connecting elements are electrolytically corrodible. Such connecting elements enable the implant, after it has been correctly positioned, to be detached from the guide wire by applying electrical energy for brief periods of time, 10 to 60 seconds, for example.


Advantageously, the medical implant according to one embodiment of the invention does not incur a longitudinal contraction when adapting to the vessel. The longitudinally open structure, having a predetermined winding property, has no effect on the longitudinal expansion of the stent. The foil structures have been found to be remarkably true to size under the influence of thrust and tensile forces. The same applies to the warp-knitted structure and the mesh-like structure consisting of individual filaments interconnected by welding.


In an embodiment where the superimposed structure cannot be impressed onto the implants with the help of the warp or weft knitting method or by braiding, material may be put to use that possesses shape-memory properties. For example, such materials consist of alloys containing titanium and nickel which are known by the name of Nitinol, as well as iron and copper based alloys. Shape-memory properties may be based on a stress-induced martensitic transformation or a temperature-induced martensitic transformation or may be the result of a combination of the two.


The implants according to one embodiment of the present invention are also provided with X-ray reflecting markers that enable the positioning and implantation to be monitored. Such markers may have the form of spirals that are arranged proximally, for example, at the connection point of the strings or filaments. The X-ray reflecting markers can also be arranged at the distal end of the implant, in the form of platinum or platinum-iridium elements incorporated in or attached to the mesh structure. The meshes of the implant, according to one embodiment the invention, may, at the distal end, be provided with a lug or end in a lug that accommodates the marker element arranged levelly.


Furthermore, the present invention operates in a combination of the implant with a guide wire that is linked to the distal end of the implant in a manner so as to be detachable. Such detachability is brought about by an element that, under the influence of electrical energy, is capable of corroding. The guide wire can be a known and applied guiding wire of suitable kind for pushing the implant through a catheter to the site of implantation and, should it have been improperly positioned, retract it into the catheter. It is clearly understood that the corrosion point may also be in the area of the guide wire or may be based on an otherwise known mechanical or thermal detachment technique.


The invention also relates to a system to be used for the treatment of aneurysms or other vascular malformations. The system comprises a first micro-catheter, a first guide wire to bring the first microcatheter into position, a second guide wire to move the implant through the first micro-catheter and place it in position and the implant arranged at the distal end of the second guide wire in a way so as to be detachable. Due to the curled up structure of the implant, and as a result of making use of the combination with the guide wire, it is possible, after having placed the first micro-catheter, to remove the first guide wire and introduce and handle the second guide wire which is provided with the implant.


As per one embodiment, the system has additionally been provided with a second micro-catheter to accommodate the second guide wire with the implant in such a way that it is slidable within the second micro-catheter and can be moved through the first micro-catheter to the target site. Coatings of the second micro-catheter that enhance its slidability may facilitate handling.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and further advantages of the invention may be better understood by referring to the following description in conjunction with the accompanying drawings in which:



FIG. 1 is an implant according to one embodiment of the present invention having a honeycomb structure;



FIG. 2 is another embodiment of a stent according to the present invention having a honeycomb structure;



FIG. 3 is a third embodiment of a stent according to the present invention having a honeycomb structure:



FIG. 4 is a warp-knitted structure as can be used for an implant according to the invention;



FIG. 5 is a stent according to the present invention together with a guide wire and a catheter;



FIGS. 6A and 6B are schematic representations of an implant according to an embodiment of the present invention shown in its superimposed and in its volume reduced shape;



FIGS. 7A and 7B show a marker element as can be used in the system according to the present invention; and



FIGS. 8A and 8B are schematic representations of two detachment locations by which the implant, according to the present invention, can be detachably linked to a guide wire.





DETAILED DESCRIPTION

An implant, according to FIG. 1 consists of a mesh or honeycomb structure that, in one embodiment, comprises a multitude of filaments interconnected by a laser welding technique. The implant can be subdivided into a functional structure A and a tapering proximal structure B, the two structures being disfinguishable, inter alia, by a different mesh size. To enable the functional structure A to perform its retaining function, its mesh cells 3 are held relatively narrow so that they lend themselves to the retention of occlusion spirals arranged in an aneurysm. In general, the mesh width is in the range of 0.5 to 4 mm and may vary with in an implant.


In one aspect of the present invention, the implant is a flat or two dimensional structure that is rolled up to form a longitudinally open object capable of establishing close contact with the wall of the vessel into which it is introduced.


In the tapering proximal structure B of the implant, there is provided a wider mesh cell 4 structure which has been optimized towards having a minimum occlusion effect. In the area of the tapering structure 2, the filaments have a greater thickness and/or width to be able to better transfer to the functional structure A the thrust and tensile forces of the guide wire exerted at a connection point 5 when the implant 1 is introduced and placed in position. In the area of the tapering structure it is normally not necessary to provide support for, and coverage of, the vessel wall, but on the other hand requirements as to tensile and thrust strength increase. The filament thickness in the functional structure A generally ranges between 0.02 and 0.070 mm, and in proximal structure part B, the filament thickness is greater than 0.076 mm.


The proximal structure forms an angle from 45° to 120° at the connection point 5, in particular an angle of about 90°. The filament thickness (or string width) is the same as the mesh size and its shape may vary over a great range to suit varying requirements as to stability, flexibility and the like. It is understood that the proximal structure B, as well, contacts the vessel wall and thus does not interfere with the flow of blood within the vessel.


At a distal end, the filaments 2 end in a series of tails 6 that are of suitable kind to carry platinum markers that facilitate the positioning of the implant.


The implant 1 is curled up in such a way that edges 7 and 8, forming first and second lateral edges, are at least closely positioned to each other and may overlap in the area of the edges. In this volume-reduced form, the implant 1, similar to a wire mesh roll, has curled up in a coiled configuration to such an extent that the roll so formed can be introduced into a micro-catheter and moved within the catheter. Having been released from the micro-catheter, the curled-up structure springs open and attempts to assume the superimposed structure previously impressed on it and in doing so closely leans to the inner wall of the vessel to be treated, thus superficially covering a fistula, vessel branch or aneurysm that exists in that location. In this case the extent of the “curl up” is governed by the vessel volume. In narrower vessels a greater overlap of the edges 7 and 8 of the implant 1 will occur whereas in wider vessels the overlap will be smaller or even “underlap,” will be encountered, and due care must be exercised to make sure the implant still exhibits a residual tension.


Suitable materials that can be employed in the device include alloys having shape-memory properties. The finished product is subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.


The implant has a mesh-like structure consisting of strings or filaments connected with each other. Strings occur if the implant comprises cut structures as, for example, are frequently put to use in coronary stents, a mesh-like structure consisting of filaments is found if the implants are present in the form of mats having knitted or braided structures or in the form of individual filaments that are welded to one another.



FIG. 2 shows another embodiment of a stent 1 according to the invention having the above described honeycomb structure where the tapering proximal structure B is connected with the functional structure part A by additional filaments 9 in a peripheral area 10 as well as in the central area. The additional filaments 9 and 10 bring about a more uniform transmission of the tensile and thrust forces from the proximal structure B to the functional structure A. As a result, the tensile forces can be better transmitted, especially if the stent might have to be repositioned by having to be retracted into the microcatheter. The additional filaments 9, 10 facilitate the renewed curling up of the stent. Similarly, the transmission of thrust forces occurring when the stent is moved out and placed in position is facilitated so that the stent can be gently applied.



FIG. 3 shows another embodiment of a stent 1 according to the invention having a honeycomb structure with the edges 7 and 8 being formed of straight filaments 9. According to this embodiment, the thrust or pressure exerted by the guide wire at the connection point 5 is directly transmitted to the edges 7 and 8 of the functional structure part A which further increases the effect described with reference to FIG. 2.


The embodiment as per FIG. 3, similar to those depicted in FIGS. 1 and 2, may be based on a cut foil, i.e., the individual filaments 2, 9 and 10 are substituted by individual strings being the remaining elements of a foil processed with the help of a cutting technique. Laser cutting techniques for the production of stents having a tubular structure are known. The processing of a foil for the production of a pattern suitable for a stent is performed analogously. The impression of the superimposed structure is carried out in the same way as is used for the filament design. In one embodiment, expanded metal foil may be used with the respective string widths being of the same magnitude. In one embodiment, it is envisioned to subsequently smooth the foil to make sure all strings are arranged on the same plane. The thickness of the foil usually ranges between 0.02 and 0.2 mm. Foils of greater thickness also permit the stent to be used in other fields of application, for example, as coronary stents or in other regions of the body including, for instance, the bile duct or ureter.


Foils worked with the help of a cutting technique are finished by electrochemical means to eliminate burrs and other irregularities to achieve a smooth surface and round edges. One of ordinary skill in the art will understand these electrochemical processes as these processes already are in use in medical technology, in this context, it is to be noted that the stents according to the invention that are based on a two-dimensional geometry and on which a three-dimensional structure is impressed subsequently can be manufactured and processed more easily than the conventional “tubular” stents that already during manufacture, have a three-dimensional structure and necessitate sophisticated and costly working processes and equipment.


As pointed out above, the mesh structure of the implant according to the invention may consist of a braiding of individual filaments. Such a knitted structure is shown in FIG. 4 where the individual filaments 2 are interwoven in the form of a “single jersey fabric” having individual loops 3 forming a mesh-like structure 11. Single jersey goods of this type are produced in a known manner from a row of needles. The single jersey goods have two fabric sides of different appearance, i.e., the right and left side of the stitches. A single jersey fabric material features minor flexibility in a transverse direction and is very light.


Filaments consisting of a braid of individual strands and formed into a rope can also be employed. Braids comprising twelve to fourteen strands having a total thickness of 0.02 mm can be used. Platinum, platinum alloys, gold and stainless steel can be used as materials for the filaments. Generally speaking, all permanent implant materials known in medical technology can be employed that satisfy the relevant requirements.


In one embodiment, it is advantageous to have the fabric rims of such a knitted structure curling up as is known, for example, from the so-called “Fluse” fabric, a German term, which is of benefit with respect to the superimposed structure and application dealt with here. In this case, the superimposed structure can be impressed by means of the knitting process. However, the use of shape-memory alloys in this case as we is feasible and useful.


For the production of such knitted structures, known knitting processes and techniques can be employed. However, since the implants according to the invention are of extremely small size—for example, a size of 2 by 1 cm—it has turned out to be beneficial to produce the implants in the framework of a conventional warp or weft knitting fabric of textile, non-metallic filaments, for example, in the form of a nm consisting of the respective metallic filaments from which the weft or warp knitting fabric either starts out or that extends from such a fabric. The arrangement of the metallic part of the weft or warp knitting fabric at the rim achieves the aforementioned curling effect. The non-metallic portions of the knitted fabric are finally removed by incineration, chemical destruction or dissolution using suitable solvents,



FIG. 5 shows a combination of a guide wire 21 with the implant 1 attached to it that consists of filaments 2 connected to each other by welding, The distal ends 6 and the connection point 5 where the filaments of the implant converge in a tapering structure and that simultaneously represents the joining iodation with guide wire 21 are shown. The guide wire 21 is introduced into a micro-catheter 22 which is of customary make.


Shifting the guide wire 21 within the catheter 22 will cause the implant 1 to be pushed out of or drawn into the catheter. Upon the stent being pushed out of the micro-catheter the mesh-like structure attempts to assume the superimposed shape impressed on it, and when being drawn in, the mesh structure folds back into the micro-catheter adapting to the space available inside,


As a result of the stiffness of its mesh structure, the implant can be moved to and fro virtually without restriction is the guide wire 21 until it has been optimally positioned within the vessel system.


As mentioned earlier, customary micro-catheters can be used. One advantage of the implant according to the invention and of the combination of implant and guide wire according to the invention is, however, that after having placed the micro-catheter in position with a customary guide wireimarker system, the combination of guide wire 21 and implant 1 according to the invention can be introduced into the micro-catheter, moved through it towards the implantation site and then moved out and applied in that position. Alternatively, it will be possible to have a second micro-catheter of smaller caliber accommodate guide wire 21 and implant 1 and with this second micro-catheter within the firstly positioned micro-catheter shift them to the implantation site. In any case, the implant can be easily guided in both directions.



FIG. 6 shows a schematic representation of an implant according to the invention in its superimposed or volume-expanded shape and in its volume-reduced shape. In its expanded shape, as illustrated in FIG. 6a, the implant 1 forms a ring-shaped structure with slightly overlapping edges land 8. In FIG. 6a the implant 1 is viewed from its proximal end as a top view with the connection point 5 being approximately positioned opposite to the edges 7 and 8. In the combination according to the invention, the guide wire 21 is affixed at the connection point 5.



FIG. 6b shows the same implant in its volume-reduced form as it is arranged, for example, in a micro-catheter in a curled up condition. In the case illustrated there is a total of two windings of the curled-up implant 1 with the connection point 5 being located at the proximal side and the two lateral edges 7 and 8 being the starting and final points of the roll or spiral. The structure is held in its volume-reduced form by the micro-catheter 22 and when the implant 1 is pushed out of the micro-catheter 22 it springs into its expanded shape, as illustrated by FIG. 6a, similar to a spiral spring.



FIG. 7a shows a marker element 12 suitable for the implant according to the invention with the marker element 12 being capable of being arranged at the distal end of the implant 1. The marker element 12 consists of a lug 13 provided with a small marker plate 15 levelly arranged inside it, i.e., flush with the plane of the implant without any projecting elements. The plate 15 is made of an X-ray reflecting material, for example, platinum or platinum-iridium. The marker plate 15 may be connected to the surrounding implant structure by known laser welding techniques. As shown in FIG. 7b, the marker elements 12 are arranged at the distal end of the implant 1.



FIGS. 8a and 8b are representations, respectively, of two variations of a separating arrangement by which the implant 1 according to the invention is detachably connected to a guide wire 21. In each case, a separating arrangement consists of a dumb-bell shaped element 23 that dissolves under the influence of electrical energy when in contact with an electrolyte. At the proximal (guide-wire side) end of the dumb-bell shaped separating element 23, as per FIG. 8a, a spiral structure 25 is located that interacts with a strengthening spiral 26 of the guide wire 21. At the distal end, a ball-shaped element 27 is arranged that with the help of a laser welding technique, is connected to a platinum spiral 28 which, in turn, is linked with the connection point 5 situated at the proximal end of the implant 1. The platinum spiral 28 also serves as an X-ray reflecting proximal marker of the implant 1.


To strengthen the joint between the ball-shaped element 27 and the connection point 5, a reinforcement wire 29 may be provided. Alternatively, the platinum spiral 28 may also be designed in such a manner that it withstands the tensile and thrust forces imposed on it.


The separating element 23 can include a steel material that is susceptible to corrosion in an electrolyte under the influence of electrical energy. To accelerate corrosion and shorten the separating time span, a structural or chemical weakening of the dumb-bell shaped element 23 may be beneficial, for example, by applying grinding methods or thermal treatment.


Generally, the portion of the dumb-bell 23 accessible to the electrolyte has a length of 0.1 to 0.5 mm, particularly 0.3 mm.


The spiral structure 25 is secured via welding both to the dumb-bell shaped element 23 and the reinforcement spiral 26 of the guide wire 21. The guide wire 21 itself is slidably accommodated within the micro-catheter 22.



FIG. 8b shows a second embodiment that differs from the one described with respect to FIG. 8a, in that the dumb-bell shaped element 23 has a ball-shaped element 27 at each end. The ball shaped elements 27 are connected distally to the connection point 5 of the implant 1 and proximally to the guide wire 21 via spirals 28, 26, respectively.


It is of course also provided that other separating principles may be applied, for example, those that are based on mechanical principles or melting off plastic connecting elements.


Although various exemplary embodiments of the present invention have been disclosed, it will be apparent to those skilled in the art that changes and modifications can be made which will achieve some of the advantages of the invention without departing from the spirit and scope of the invention. It will be apparent to those reasonably skilled in the art that other components performing the same functions may be suitably substituted.

Claims
  • 1. A medical device comprising: a guide wire;a longitudinally open laser-cut structure consisting of: a first portion consisting of a laser-cut mesh of individual filaments defining a first plurality of cells, and having a distal end and a proximal end, the first portion forming a longitudinal tube, the distal end of the first portion being open; anda second portion consisting of a laser-cut mesh of individual filaments defining a second plurality of cells, and having a distal end and a proximal end, the second portion located proximal to the first portion, and the distal end of the second portion attached to the proximal end of the first portion,wherein each of the cells of the first portion are smaller than each of the cells of the second portion; anda connection between the guide wire and the longitudinally open structure at the proximal end of the second portion,wherein the proximal end of the second portion is open and tapers toward the connection, and the guide wire extends proximally of the proximal end of the second portion and is configured to introduce the first and second portions through a microcatheter.
  • 2. The medical device of claim 1, wherein the longitudinal tube is self-expandable due to shape memory of the first portion.
  • 3. The medical device of claim 1, wherein the cells of the first portion are smaller, in a latitudinal direction of the medical device, than the cells of the second portion.
  • 4. The medical device of claim 1, wherein at least one of the first or second portions comprises Nitinol.
  • 5. The medical device of claim 1, wherein the device is retractable proximally by the guide wire into a catheter to collapse the longitudinal tube.
  • 6. The medical device of claim 1, wherein the guide wire is detachably coupled to the second portion.
  • 7. The medical device of claim 6, wherein the connection comprises an electrolytically corrodible element.
  • 8. The medical device of claim 1, wherein the guide wire comprises a spiral.
  • 9. The medical device of claim 1, wherein the connection comprises a spiral.
  • 10. The medical device of claim 1, wherein the connection is X-ray reflecting.
  • 11. The medical device of claim 1, further comprising a plurality of markers attached to the longitudinally open structure.
  • 12. A medical device comprising: a longitudinally open structure consisting of: a first portion consisting of a laser-cut mesh of individual filaments defining a first plurality of cells, and having a distal end and a proximal end, the first portion forming a longitudinal tube, the distal end of the first portion being open; anda second portion consisting of a laser-cut mesh of individual filaments defining a second plurality of cells, and having a distal end and a proximal end, the second portion located proximal to the first portion, and the distal end of the second portion attached to the proximal end of the first portion, the proximal end of the second portion tapering toward a connection point, wherein the cells of the first portion are smaller than the cells of the second portion,wherein a first lateral edge extends from the distal end of the first portion to the proximal end of the second portion and a second lateral edge extends from the distal end of the first portion to the proximal end of the second portion, the first and second lateral edges being overlapped by a first amount in a coiled configuration when the medical device is in a volume-reduced form, the first and second lateral edges being overlapped by a second amount less than the first amount when the medical device is in a volume-expanded form; anda guide wire coupled to the proximal end of the second portion at the connection point, the guide wire extending proximally from the connection point and configured to introduce the longitudinally open structure through a microcatheter.
  • 13. The medical device of claim 12, wherein the longitudinal tube is self-expandable due to shape memory of the first portion.
  • 14. The medical device of claim 12, wherein at least one of the first or second portions comprises Nitinol.
  • 15. The medical device of claim 12, wherein the device is retractable proximally by the guide wire into a catheter to collapse the longitudinal tube.
  • 16. The medical device of claim 12, wherein the guide wire is detachably coupled to the second portion.
  • 17. The medical device of claim 16, wherein the connection point comprises an electrolytically corrodible element.
  • 18. The medical device of claim 12, wherein the guide wire comprises a spiral.
  • 19. The medical device of claim 12, wherein the connection point comprises a spiral.
  • 20. The medical device of claim 12, wherein the connection point is X-ray reflecting.
  • 21. The medical device of claim 12, further comprising a plurality of markers attached to the longitudinally open structure.
Priority Claims (1)
Number Date Country Kind
10233085.9 Jul 2002 DE national
RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 14/136,281, filed Dec. 20, 2013, which is a continuation of U.S. patent application Ser. No. 11/935,252, filed Nov. 5, 2007, now U.S. Pat. No. 8,632,584, which is a continuation of U.S. patent application Ser. No. 11/039,066, filed Jan. 19, 2005, now U.S. Pat. No. 7,300,458, which is a continuation of PCT International Application No. PCT/EP2003/007926 filed Jul. 21, 2003, which claims priority of German Patent Application No. 102 33 085.9 filed Jul. 19, 2002, the contents of all of which are incorporated herein by reference.

US Referenced Citations (356)
Number Name Date Kind
3996938 Clark, III Dec 1976 A
4046150 Schwartz et al. Sep 1977 A
4299255 Miller Nov 1981 A
4347846 Dormia Sep 1982 A
4403612 Fogarty Sep 1983 A
4611594 Grayhack et al. Sep 1986 A
4612931 Dormia Sep 1986 A
4650466 Luther Mar 1987 A
4655771 Wallsten Apr 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4793348 Palmaz Dec 1988 A
4820298 Leveen et al. Apr 1989 A
4890611 Monfort et al. Jan 1990 A
5064435 Porter Nov 1991 A
5071407 Termin et al. Dec 1991 A
5100423 Fearnot Mar 1992 A
5102417 Palmaz Apr 1992 A
5190058 Jones et al. Mar 1993 A
5192286 Phan et al. Mar 1993 A
5195984 Schatz Mar 1993 A
5197978 Hess Mar 1993 A
5217484 Marks Jun 1993 A
5222971 Willard et al. Jun 1993 A
5330482 Gibbs et al. Jul 1994 A
5354295 Guglielmi et al. Oct 1994 A
5411549 Peters May 1995 A
5423829 Pham et al. Jun 1995 A
5456667 Ham et al. Oct 1995 A
5490859 Mische et al. Feb 1996 A
5496330 Bates et al. Mar 1996 A
5501694 Ressemann et al. Mar 1996 A
5527326 Hermann et al. Jun 1996 A
5540680 Guglielmi et al. Jul 1996 A
5540707 Ressemann et al. Jul 1996 A
5569245 Guglielmi et al. Oct 1996 A
5571122 Kelly et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5624449 Pham et al. Apr 1997 A
5669933 Simon et al. Sep 1997 A
5690667 Gia Nov 1997 A
5695519 Summers et al. Dec 1997 A
5720764 Naderlinger Feb 1998 A
5725572 Lam et al. Mar 1998 A
5743905 Eder et al. Apr 1998 A
5749883 Halpern May 1998 A
5759192 Saunders Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5792145 Bates et al. Aug 1998 A
5792157 Mische et al. Aug 1998 A
5800454 Jacobsen et al. Sep 1998 A
5800519 Sandock Sep 1998 A
5800520 Fogarty et al. Sep 1998 A
5800525 Bachinski et al. Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5824037 Fogarty et al. Oct 1998 A
5827304 Hart Oct 1998 A
5836868 Ressemann et al. Nov 1998 A
5848964 Samuels Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5882329 Patterson et al. Mar 1999 A
5891128 Gia et al. Apr 1999 A
5893887 Jayaraman Apr 1999 A
5895385 Guglielmi et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5904698 Thomas et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5913895 Burpee et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919187 Guglielmi et al. Jul 1999 A
5925037 Guglielmi et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5928226 Guglielmi et al. Jul 1999 A
5935139 Bates Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5944714 Guglielmi et al. Aug 1999 A
5947962 Guglielmi et al. Sep 1999 A
5947995 Samuels Sep 1999 A
5948016 Jang Sep 1999 A
5954743 Jang Sep 1999 A
5964797 Ho Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5976126 Guglielmi Nov 1999 A
5976131 Guglielmi et al. Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
6010498 Guglielmi Jan 2000 A
6013093 Nott et al. Jan 2000 A
6039721 Johnson et al. Mar 2000 A
6063100 Diaz et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6077260 Wheelock et al. Jun 2000 A
6083220 Guglielmi et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096053 Bates Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6118001 Owen et al. Sep 2000 A
6123714 Gia et al. Sep 2000 A
6129755 Mathis et al. Oct 2000 A
6146396 Konya et al. Nov 2000 A
6156061 Wallace et al. Dec 2000 A
6165178 Bashiri et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168603 Leslie et al. Jan 2001 B1
6179857 Diaz et al. Jan 2001 B1
6187017 Gregory, Jr. Feb 2001 B1
6190394 Lind et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6203552 Bagley et al. Mar 2001 B1
6214025 Thistle et al. Apr 2001 B1
6238412 Dubrul et al. May 2001 B1
6241746 Bosma et al. Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6254571 Hart Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6264687 Tomonto Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6273900 Nott et al. Aug 2001 B1
6277125 Barry et al. Aug 2001 B1
6277126 Barry et al. Aug 2001 B1
6306141 Jervis Oct 2001 B1
6312463 Rourke et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6371969 Tsugita et al. Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6383205 Samson et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6409721 Wheelock et al. Jun 2002 B1
6425893 Guglielmi Jul 2002 B1
6425914 Wallace et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443972 Bosma et al. Sep 2002 B1
6458139 Palmer et al. Oct 2002 B1
6468266 Bashiri et al. Oct 2002 B1
6485524 Strecker Nov 2002 B2
6491719 Fogarty et al. Dec 2002 B1
6500182 Foster Dec 2002 B2
6514273 Voss et al. Feb 2003 B1
6520968 Bates et al. Feb 2003 B2
6530935 Wensel et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6551342 Shen et al. Apr 2003 B1
6554849 Jones et al. Apr 2003 B1
6572648 Klumb et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6589230 Gia et al. Jul 2003 B2
6589236 Wheelock et al. Jul 2003 B2
6592607 Palmer et al. Jul 2003 B1
6620152 Guglielmi Sep 2003 B2
6641590 Palmer et al. Nov 2003 B1
6645224 Gilson et al. Nov 2003 B2
6652548 Evans et al. Nov 2003 B2
6656214 Fogarty et al. Dec 2003 B1
6660014 Demarais et al. Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6673106 Mitelberg et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6692508 Wensel et al. Feb 2004 B2
6702782 Miller et al. Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6716238 Elliott Apr 2004 B2
6723108 Jones et al. Apr 2004 B1
6743236 Barry et al. Jun 2004 B2
6811560 Jones et al. Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6833002 Stack et al. Dec 2004 B2
6833003 Jones et al. Dec 2004 B2
6878151 Carrison et al. Apr 2005 B2
6887268 Butaric et al. May 2005 B2
6893413 Martin May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6921414 Klumb et al. Jul 2005 B2
6945977 Demarais et al. Sep 2005 B2
6953468 Jones et al. Oct 2005 B2
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6960228 Mitelberg et al. Nov 2005 B2
6974473 Barclay et al. Dec 2005 B2
6989020 Jones et al. Jan 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7004956 Palmer et al. Feb 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041116 Goto et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7058456 Pierce Jun 2006 B2
7101380 Khachin et al. Sep 2006 B2
7128073 Van der Burg et al. Oct 2006 B1
7147659 Jones Dec 2006 B2
7156871 Jones et al. Jan 2007 B2
7172617 Colgan et al. Feb 2007 B2
7179273 Palmer et al. Feb 2007 B1
7179276 Barry et al. Feb 2007 B2
7182774 Barry et al. Feb 2007 B2
7195648 Jones et al. Mar 2007 B2
7201769 Jones et al. Apr 2007 B2
7232432 Fulton, III et al. Jun 2007 B2
7264628 Jones et al. Sep 2007 B2
7270674 Jones et al. Sep 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7294123 Jones et al. Nov 2007 B2
7306622 Jones et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311726 Mitelberg et al. Dec 2007 B2
7323000 Monstdt et al. Jan 2008 B2
7344550 Carrison et al. Mar 2008 B2
7344558 Lorenzo et al. Mar 2008 B2
7351255 Andreas Apr 2008 B2
7357809 Jones et al. Apr 2008 B2
7367987 Balgobin et al. May 2008 B2
7371251 Mitelberg et al. May 2008 B2
7371252 Balgobin et al. May 2008 B2
7377932 Mitelberg et al. May 2008 B2
7481821 Fogarty et al. Jan 2009 B2
7485122 Teoh Feb 2009 B2
7510565 Gilson et al. Mar 2009 B2
7517352 Evans et al. Apr 2009 B2
7524319 Dubrul Apr 2009 B2
7534252 Sepetka et al. May 2009 B2
7549974 Nayak Jun 2009 B2
7553314 Khachin et al. Jun 2009 B2
7553321 Litzenberg et al. Jun 2009 B2
7582101 Jones et al. Sep 2009 B2
7780694 Palmer et al. Aug 2010 B2
7833240 Okushi et al. Nov 2010 B2
8052640 Fiorella et al. Nov 2011 B2
8062307 Sepetka et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8100935 Rosenbluth et al. Jan 2012 B2
8105333 Sepetka et al. Jan 2012 B2
8197493 Ferrera et al. Jun 2012 B2
8357179 Grandfield et al. Jan 2013 B2
8603014 Alleman et al. Dec 2013 B2
8632584 Henkes et al. Jan 2014 B2
8837800 Bammer et al. Sep 2014 B1
9119656 Bose et al. Sep 2015 B2
9126018 Garrison Sep 2015 B1
9211132 Bowman Dec 2015 B2
9241699 Kume et al. Jan 2016 B1
9265512 Garrison et al. Feb 2016 B2
9308007 Cully et al. Apr 2016 B2
9399118 Kume et al. Jul 2016 B2
9445828 Turjman et al. Sep 2016 B2
9445829 Brady et al. Sep 2016 B2
9492637 Garrison et al. Nov 2016 B2
9539022 Bowman Jan 2017 B2
9561345 Garrison et al. Feb 2017 B2
9579119 Cully et al. Feb 2017 B2
9585741 Ma Mar 2017 B2
9642635 Vale et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9737318 Monstadt et al. Aug 2017 B2
9770251 Bowman et al. Sep 2017 B2
9801643 Hansen et al. Oct 2017 B2
9861783 Garrison et al. Jan 2018 B2
9993257 Losordo et al. Jun 2018 B2
10028782 Orion Jul 2018 B2
10029008 Creighton Jul 2018 B2
10039906 Kume et al. Aug 2018 B2
20010003801 Strecker Jun 2001 A1
20010029351 Falotico et al. Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041899 Foster Nov 2001 A1
20010044649 Vallana et al. Nov 2001 A1
20010047200 White et al. Nov 2001 A1
20010053929 Vonesh et al. Dec 2001 A1
20020016597 Dwyer et al. Feb 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020188341 Elliott Dec 2002 A1
20020193868 Mitelberg et al. Dec 2002 A1
20030120208 Houser Jun 2003 A1
20030153944 Phung et al. Aug 2003 A1
20040010308 Zafrir-pachter et al. Jan 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040068314 Jones et al. Apr 2004 A1
20040078050 Monstadt et al. Apr 2004 A1
20040098025 Sepetka et al. May 2004 A1
20040116996 Freitag Jun 2004 A1
20050021125 Stack et al. Jan 2005 A1
20050033348 Sepetka et al. Feb 2005 A1
20050165441 Mcguckin et al. Jul 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050222676 Shanley et al. Oct 2005 A1
20060085065 Krause et al. Apr 2006 A1
20060195118 Richardson Aug 2006 A1
20060224179 Kucharczyk et al. Oct 2006 A1
20070179513 Deutsch Aug 2007 A1
20070185501 Martin et al. Aug 2007 A1
20070198029 Martin et al. Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070266542 Melsheimer Nov 2007 A1
20070288038 Bimbo Dec 2007 A1
20080039930 Jones Feb 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080119888 Huffmaster May 2008 A1
20080183185 Miller et al. Jul 2008 A1
20080183198 Sepetka et al. Jul 2008 A1
20080188865 Miller et al. Aug 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20090069828 Martin et al. Mar 2009 A1
20090163851 Holloway et al. Jun 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20100174309 Fulkerson et al. Jul 2010 A1
20120083868 Shrivastava et al. Apr 2012 A1
20130030461 Marks et al. Jan 2013 A1
20130281788 Garrison Oct 2013 A1
20140276074 Warner Sep 2014 A1
20140343595 Monstadt et al. Nov 2014 A1
20150359547 Vale et al. Dec 2015 A1
20160015402 Brady et al. Jan 2016 A1
20160015935 Chan et al. Jan 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160151618 Powers et al. Jun 2016 A1
20160157985 Vo et al. Jun 2016 A1
20160199620 Pokorney et al. Jul 2016 A1
20160296690 Kume et al. Oct 2016 A1
20160302808 Loganathan et al. Oct 2016 A1
20160375180 Anzai Dec 2016 A1
20170079766 Wang et al. Mar 2017 A1
20170079767 Leon-yip Mar 2017 A1
20170086862 Vale et al. Mar 2017 A1
20170100143 Grandfield Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170164963 Goyal Jun 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170290599 Youn et al. Oct 2017 A1
20180049762 Seip et al. Feb 2018 A1
20180084982 Yamashita et al. Mar 2018 A1
20180116717 Taff et al. May 2018 A1
20180132876 Zaidat May 2018 A1
20180140314 Goyal et al. May 2018 A1
20180140315 Bowman et al. May 2018 A1
20180140354 Lam et al. May 2018 A1
20180185614 Garrison et al. Jul 2018 A1
Foreign Referenced Citations (91)
Number Date Country
9604566-3 Sep 1998 BR
2389374 May 2001 CA
2804058 Aug 1978 DE
2821048 Nov 1979 DE
8435489 Aug 1986 DE
19703482 Aug 1998 DE
0201466 Nov 1986 EP
0484468 May 1992 EP
0585326 Mar 1994 EP
0629125 Dec 1994 EP
0707830 Apr 1996 EP
0719522 Jul 1996 EP
0726745 Aug 1996 EP
0737450 Oct 1996 EP
0739606 Oct 1996 EP
0750886 Jan 1997 EP
0752236 Jan 1997 EP
0759730 Mar 1997 EP
0800790 Oct 1997 EP
0803230 Oct 1997 EP
0804904 Nov 1997 EP
0804905 Nov 1997 EP
0804906 Nov 1997 EP
0807410 Nov 1997 EP
0820729 Jan 1998 EP
0826341 Mar 1998 EP
0826342 Mar 1998 EP
0832606 Apr 1998 EP
0861634 Sep 1998 EP
0914803 May 1999 EP
0964659 Dec 1999 EP
1005837 Jun 2000 EP
1009295 Jun 2000 EP
1009296 Jun 2000 EP
10010840 Sep 2001 EP
1225844 Jul 2002 EP
1266639 Dec 2002 EP
1266640 Dec 2002 EP
1323385 Jul 2003 EP
1329196 Jul 2003 EP
1351626 Oct 2003 EP
1366720 Dec 2003 EP
1400219 Mar 2004 EP
2319575 Nov 2013 EP
2343488 Oct 1977 FR
2020557 Nov 1979 GB
2-95359 Apr 1990 JP
02255157 Oct 1990 JP
8-033719 Feb 1996 JP
2975584 Nov 1999 JP
2001178830 Jul 2001 JP
2001190686 Jul 2001 JP
2003527925 Sep 2003 JP
2014004219 Jan 2014 JP
6098939 Mar 2017 JP
6246004 Dec 2017 JP
2018118132 Aug 2018 JP
20180102877 Sep 2018 KR
WO 9617634 Jun 1996 WO
WO 9628116 Sep 1996 WO
WO 974711 Feb 1997 WO
WO 9825656 Oct 1998 WO
WO 9855175 Dec 1998 WO
WO 9916382 Apr 1999 WO
WO 9923976 May 1999 WO
WO 9925252 May 1999 WO
WO 9929264 Jun 1999 WO
WO 9944542 Sep 1999 WO
WO 9948429 Sep 1999 WO
WO 9948440 Sep 1999 WO
WO 00012166 Mar 2000 WO
WO 0059405 Oct 2000 WO
WO 0132099 May 2001 WO
WO 0145566 Jun 2001 WO
WO 0172240 Oct 2001 WO
WO 0193780 Dec 2001 WO
WO 02054980 Jul 2002 WO
WO 2004008991 Jan 2004 WO
WO 2008063156 May 2008 WO
WO 2009105710 Aug 2009 WO
WO 2015141317 Sep 2015 WO
WO 2017192999 Nov 2017 WO
WO 2018019829 Feb 2018 WO
WO 2018033401 Feb 2018 WO
WO 2018046408 Mar 2018 WO
WO 2018137029 Aug 2018 WO
WO 2018137030 Aug 2018 WO
WO 2018145212 Aug 2018 WO
WO 2018156813 Aug 2018 WO
WO 2018172891 Sep 2018 WO
WO 2018187776 Oct 2018 WO
Non-Patent Literature Citations (2)
Entry
European Search Report dated Jan. 21, 2016; European Patent Application No. 15190138.6; 2 pages.
Schumacher, H., “Endovascular Mechanical Thrombectomy of an Occluded Superior Division Branch of the Left MCA for Acute Cardioembolic Stroke.” Cardiovascular and Interventional Radiology, Jun. 2003 26(3) pp. 305-308.
Related Publications (1)
Number Date Country
20190307585 A1 Oct 2019 US
Continuations (4)
Number Date Country
Parent 14136281 Dec 2013 US
Child 16420814 US
Parent 11935252 Nov 2007 US
Child 14136281 US
Parent 11039066 Jan 2005 US
Child 11935252 US
Parent PCT/EP03/07926 Jul 2003 US
Child 11039066 US